Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01330966
Other study ID # AAPSMCS1002
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date April 2011
Est. completion date February 2018

Study information

Verified date March 2023
Source George Clinical Pty Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the effectiveness and safety of single agent pazopanib in subjects with chondrosarcoma.


Description:

This research study is being conducted in adult subjects with a type of bone cancer called chondrosarcoma that has spread to other parts of the body and is not able to be removed with surgery. There is only one study drug that will be used in this study. It is a drug that interferes with cell communication and growth, taken orally. The study drug is called pazopanib.


Recruitment information / eligibility

Status Completed
Enrollment 47
Est. completion date February 2018
Est. primary completion date February 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Written informed consent. - Age > or = to 18 years. - Histologically confirmed diagnosis of conventional chondrosarcoma of any grade. - Surgically unresectable or metastatic disease. - Any number of prior treatment regimens, including treatment naive subjects. Prior treatment with tyrosine kinase inhibitors is permitted. - Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2. - Measurable or evaluable (non-measurable) disease per RECIST guidelines version 1.1. - Adequate organ system function determined within 14 days prior to first dose of study treatment. - Left ventricular ejection fraction > 50% or the institutional LLN within 28 days prior to the first dose of study treatment. - Females must either be of non-child bearing potential or have a negative serum pregnancy test within 7 days prior to the first dose of study treatment. Exclusion Criteria: - Prior treatment with pazopanib. - Mesenchymal, dedifferentiated, and extraskeletal myxoid chondrosarcoma subtypes. - Prior malignancy (Note: subjects who have had another malignancy and have been disease-free for 3 years, or subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible). - History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis, unless previously treated, asymptomatic, and off steroids and anti-seizure medication for 6 months prior to first dose of study drug. - Clinically significant gastrointestinal (GI) abnormalities that may increase the risk for GI bleeding. - Clinically significant GI abnormalities that may affect absorption of investigational product. - Presence of uncontrolled infection. - Corrected QT interval > 480 msecs using Bazett's formula. - History of certain cardiovascular conditions within the past 6 months. - Poorly controlled hypertension [defined as systolic blood pressure of > or = 140 mmHg or diastolic blood pressure of > or = 90 mmHg]. - History of cerebrovascular accident including transient ischemic attack, pulmonary embolism, or untreated deep venous thrombosis within the past 6 months. - Prior major surgery or trauma within 28 days prior to the first dose of study drug and/or presence of any non-healing wound, fracture, or ulcer. - Evidence of active bleeding or bleeding diathesis. - Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels that increase the risk of pulmonary hemorrhage. - Hemoptysis in excess of 2.5 mL within 8 weeks of first dose of study drug. - Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures. - Unable or unwilling to discontinue use of prohibited medications for at least 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug and for the duration of study treatment. - Radiation therapy, surgery (except major surgery), tumor embolization, chemotherapy, immunotherapy, biologic therapy, investigational therapy, or hormonal therapy within 14 days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug. - Any ongoing toxicity from prior anti-cancer therapy that is > Grade 1 and/or that is progressing in severity, except alopecia. - Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib or excipients that contraindicates participation.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
pazopanib
Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.

Locations

Country Name City State
United Kingdom University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre Edgbaston Birmingham
United States City of Hope Duarte California
United States MD Anderson Houston Texas
United States University of Iowa Iowa City Iowa
United States Edward Cancer Center Naperville Illinois
United States Pennsylvania Oncology Hematology Associates Philadelphia Pennsylvania
United States Mayo Clinic Rochester Minnesota

Sponsors (2)

Lead Sponsor Collaborator
George Clinical Pty Ltd GlaxoSmithKline

Countries where clinical trial is conducted

United States,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Disease Control at Week 16 Disease control at week 16 defined as complete response (CR), Disappearance of all target lesions; plus partial response (PR), At least a 30% decrease in the sum of diameters of the target lesions taking as reference the Baseline sum diameters; plus stable disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum diameters while on the study; where tumor response is defined by RECIST (Response Evaluation Criteria in Solid Tumors) guidelines version 1.1. Repeat radiologic imaging is performed after every 2 cycles of treatment (approximately every 8 weeks). Assessed at week 16 of study treatment
Secondary Progression Free Survival (PFS) The time origin for PFS will be cycle 1 day 1. Repeat radiologic imaging will be conducted after every 2 cycles of treatment (approximately every 8 weeks). No upper limits of duration of assessment are identified or defined in the protocol. Cycle 1 day 1 until the subject experiences disease progression
Secondary Overall Survival (OS) The time origin for OS will be cycle 1 day 1. Subjects will be followed until 6 months after end of treatment, lost to follow-up, or withdrawal of consent. No upper limits of duration of assessment are identified or defined in the protocol. Cycle 1 day 1 until 6 months after end of treatment, is lost to follow-up, or withdraws consent
See also
  Status Clinical Trial Phase
Recruiting NCT05039801 - IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Phase 1
Recruiting NCT04553692 - Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers Phase 1
Recruiting NCT06029218 - Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy N/A
Recruiting NCT04040205 - Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration Phase 2
Not yet recruiting NCT06029478 - Understanding Engagement Trends in Chondrosarcoma Clinical Trials
Completed NCT01553539 - Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery Phase 2
Completed NCT00004241 - 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma Phase 1
Active, not recruiting NCT04521686 - Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Phase 1
Recruiting NCT03715933 - Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas Phase 1
Completed NCT02496741 - Metformin And Chloroquine in IDH1/2-mutated Solid Tumors Phase 1/Phase 2
Recruiting NCT04028479 - The Registry of Oncology Outcomes Associated With Testing and Treatment
Terminated NCT00543712 - A Study of PRO95780 in Patients With Advanced Chondrosarcoma (APM4171g) Phase 2
Recruiting NCT05861245 - Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base N/A
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Recruiting NCT04278781 - AG-120 in People With IDH1 Mutant Chondrosarcoma Phase 2
Recruiting NCT04055220 - Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas N/A
Recruiting NCT04673942 - A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors Phase 2
Completed NCT01609179 - IPI-926 Extension Protocol for Continuation of Treatment With IPI-926 N/A
Completed NCT01560260 - Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors Phase 2
Recruiting NCT06387485 - A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning N/A